文献速递神经免疫

花生四烯酸衍生脂质介质与复发型和进展型多发性硬化患者疾病严重程度的关联

Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
PubMed 文献 · Neurology · 2023-06-08

该横断面人群队列研究对170例复发缓解型多发性硬化、115例进展型多发性硬化和125名健康对照的血浆脂质介质进行靶向液相色谱-串联质谱检测,发现进展型患者多种花生四烯酸衍生物升高,其中15-羟基二十碳四烯酸与残疾评分、血清神经丝轻链及脑容量等指标相关,提示ω-6脂质介质可能参与多发性硬化发病机制。

要点

  • 进展型多发性硬化患者的花生四烯酸衍生物水平显著高于复发缓解型患者和健康对照。
  • 15-羟基二十碳四烯酸与扩展残疾状况量表评分及血清神经丝轻链相关(r=0.24,p<0.001)。
  • 进展型患者中15-羟基二十碳四烯酸水平越高,全脑和深部灰质体积越低。

核心结论

  • 在同一年份出生的多发性硬化患者中,ω-3和ω-6脂质介质与残疾、生化指标(血清神经丝轻链、胶质纤维酸性蛋白)及MRI指标相关。
  • 尤其在进展型多发性硬化患者中,花生四烯酸通路的特定产物如15-羟基二十碳四烯酸升高与神经退行性过程相关。
  • 研究结果提示ω-6脂质介质在多发性硬化发病机制中可能具有相关性。

研究设计与样本

  • 采用靶向高效液相色谱-串联质谱法检测Project Y队列中多发性硬化患者和健康对照的血浆样本,该队列为横断面人群队列,包含1966年出生于荷兰的多发性硬化患者及年龄匹配的健康对照。
  • 研究样本包括170例复发缓解型多发性硬化患者、115例进展型多发性硬化患者和125名健康对照。
  • 比较患者与健康对照的脂质介质水平,并与血清神经丝轻链、血清胶质纤维酸性蛋白、扩展残疾状况量表评分及脑容量进行相关性分析,最后将显著相关因素纳入后向多变量回归模型。

主要发现

  • 进展型多发性硬化患者的脂质介质谱与复发缓解型患者及健康对照显著不同,尤其表现为多种花生四烯酸衍生物水平升高。
  • 15-羟基二十碳四烯酸与临床和生化参数如扩展残疾状况量表评分及血清神经丝轻链相关(r=0.24,p<0.001),平均r=0.2,p<0.05。
  • 在进展型多发性硬化患者中,较高的15-羟基二十碳四烯酸水平与较低的全脑体积(r=-0.24,p=0.04)和深部灰质体积(r=-0.27,p=0.02)相关。
  • 在所有多发性硬化患者中,较高的15-羟基二十碳四烯酸水平与较高的病灶体积相关(r=0.15,p=0.03)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Excessive activation of certain lipid mediator (LM) pathways plays a role in the complex pathogenesis of multiple sclerosis (MS). However, the relationship between bioactive LMs and different aspects of CNS-related pathophysiologic processes remains largely unknown. Therefore, in this study, we assessed the association of bioactive LMs belonging to the ω-3/ω-6 lipid classes with clinical and biochemical (serum neurofilament light [sNfL] and serum glial fibrillary acidic protein [sGFAP]) parameters and MRI-based brain volumes in patients with MS (PwMS) and healthy controls (HCs). METHODS: A targeted high-performance liquid chromatography-tandem mass spectrometry approach was used on plasma samples of PwMS and HCs of the Project Y cohort, a cross-sectional population-based cohort that contains PwMS all born in 1966 in the Netherlands and age-matched HCs. LMs were compared between PwMS and HCs and were correlated with levels of sNfL, sGFAP, disability (Expanded Disability Status Scale [EDSS]), and brain volumes. Finally, significant correlates were included in a backward multivariate regression model to identify which LMs best related to disability. RESULTS: The study sample consisted of 170 patients with relapsing remitting MS (RRMS), 115 patients with progressive MS (PMS), and 125 HCs. LM profiles of patients with PMS significantly differed from those of patients with RRMS and HCs, particularly patients with PMS showed elevated levels of several arachidonic acid (AA) derivatives. In particular, 15-hydroxyeicosatetraenoic acid (HETE) (r = 0.24, p < 0.001) correlated (average r = 0.2, p < 0.05) with clinical and biochemical parameters such as EDSS and sNfL. In addition, higher 15-HETE levels were related to lower total brain (r = -0.24, p = 0.04) and deep gray matter volumes (r = -0.27, p = 0.02) in patients with PMS and higher lesion volume (r = 0.15, p = 0.03) in all PwMS. DISCUSSION: In PwMS of the same birth year, we show that ω-3 and ω-6 LMs are associated with disability, biochemical parameters (sNfL, GFAP), and MRI measures. Furthermore, our findings indicate that, particularly, in patients with PMS, elevated levels of specific products of the AA pathway, such as 15-HETE, associate with neurodegenerative processes. Our findings highlight the potential relevance of ω-6 LMs in the pathogenesis of MS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Broos JY, Loonstra FC, de Ruiter LRJ, et al. Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis. Neurology. 2023. PMID: 37290971. doi:10.1212/WNL.0000000000207459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。